PYC Stock Overview
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of RNA therapeutics in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
PYC Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.091 |
| 52 Week High | AU$0.12 |
| 52 Week Low | AU$0.05 |
| Beta | 0.63 |
| 1 Month Change | 9.64% |
| 3 Month Change | 5.81% |
| 1 Year Change | 42.19% |
| 3 Year Change | -48.00% |
| 5 Year Change | 313.64% |
| Change since IPO | -65.00% |
Recent News & Updates
Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth
Apr 10
Is PYC Therapeutics (ASX:PYC) In A Good Position To Deliver On Growth Plans?
Nov 10Recent updates
Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth
Apr 10Is PYC Therapeutics (ASX:PYC) In A Good Position To Deliver On Growth Plans?
Nov 10We Think PYC Therapeutics (ASX:PYC) Needs To Drive Business Growth Carefully
Jul 03Here's Why We're Watching PYC Therapeutics' (ASX:PYC) Cash Burn Situation
Jan 25Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth
Jul 31We're Not Very Worried About PYC Therapeutics' (ASX:PYC) Cash Burn Rate
Mar 28Non-Executive Chair of the Board Alan Tribe Just Bought A Handful Of Shares In PYC Therapeutics Limited (ASX:PYC)
Feb 20
Have Insiders Been Selling PYC Therapeutics Limited (ASX:PYC) Shares?
Jan 26What You Need To Know About PYC Therapeutics Limited's (ASX:PYC) Investor Composition
Dec 22We Think PYC Therapeutics (ASX:PYC) Can Easily Afford To Drive Business Growth
Nov 17Shareholder Returns
| PYC | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -5.2% | -3.0% | -2.2% |
| 1Y | 42.2% | -9.0% | 4.5% |
Return vs Industry: PYC exceeded the Australian Biotechs industry which returned -9% over the past year.
Return vs Market: PYC exceeded the Australian Market which returned 4.5% over the past year.
Price Volatility
| PYC volatility | |
|---|---|
| PYC Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: PYC has not had significant price volatility in the past 3 months.
Volatility Over Time: PYC's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Rohan Hockings | pyctx.com |
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of RNA therapeutics in Australia. The company’s preclinical development programs include VP-001, a drug program for retinitis pigmentosa type 11; PYC-001, a drug program for the treatment of autosomal dominant optic atrophy; and PYC-002 a drug program for the treatment of a severe neurodevelopmental disorder. It also focuses on the development of programs for kidney, neurodevelopmental, retinal, and central nervous system diseases.
PYC Therapeutics Limited Fundamentals Summary
| PYC fundamental statistics | |
|---|---|
| Market cap | AU$424.84m |
| Earnings (TTM) | -AU$21.65m |
| Revenue (TTM) | AU$21.24m |
19.2x
P/S Ratio-18.8x
P/E RatioIs PYC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PYC income statement (TTM) | |
|---|---|
| Revenue | AU$21.24m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$21.24m |
| Other Expenses | AU$42.89m |
| Earnings | -AU$21.65m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0048 |
| Gross Margin | 100.00% |
| Net Profit Margin | -101.90% |
| Debt/Equity Ratio | 0% |
How did PYC perform over the long term?
See historical performance and comparison